The most important development of 2000 in competition law for Intellectual Property (“IP”) advisors is, probably, the judgment in the Court of First Instance (“CFI”) in Bayer v. Commission. Preventing traders buying medicines in countries where the government permits them to be sold only at prices well below world levels has long created problems. Parallel traders then sell them in countries where the maximum price is higher.
'Consent' In Relation To Curbs of Parallel Trade In Europe,
25 Fordham Int'l L.J. 972
Available at: http://ir.lawnet.fordham.edu/ilj/vol25/iss4/4